首页 正文

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

{{output}}
Background: Giant-cell arteritis is a systemic vasculitis with limited treatment options. The efficacy and safety of upadacitinib - a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, includin... ...